                         SEQUENCE LISTING

<110>  Janssen Biotech, Inc.
       Kristopher Barnthouse
       Subinay Ganguly
       Maarten Groeneveld
       Manuel Lopez
       Michael Nedved
       Kevin D. Smith
 
<120>  METHODS FOR PRODUCING ANTI-TNF ANTIBODY COMPOSITIONS

<130>  JBI6054WOPCT1

<140>  To Be Assigned
<141>  Herewith

<140>  62/818,316 
<141>  2019-03-14

<160>  38    

<170>  PatentIn version 3.5

<210>  1
<211>  5
<212>  PRT
<213>  Homo sapiens


<220>
<221>  MISC_FEATURE
<222>  (1)..(5)
<223>  Heavy Chain complementarity determining region 1 (CDR1).

<400>  1

Ser Tyr Ala Met His 
1               5   


<210>  2
<211>  17
<212>  PRT
<213>  Homo sapiens


<220>
<221>  MISC_FEATURE
<222>  (1)..(17)
<223>  Heavy Chain complementarity determining region 2 (CDR2).

<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa at position 1 is selected from Ile, Phe or Val.

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa at position 2 is selected from Ile or Met.

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Xaa at position 3 is selected from Ser or Leu.

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Xaa at position 4 is selected from Tyr or Phe.

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Xaa at position 10 is selected from Lys or Tyr.

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  Xaa at position 11 is selected from Ser or Tyr.

<220>
<221>  MISC_FEATURE
<222>  (17)..(17)
<223>  Xaa at position 17 is selected from Asp or Gly.

<400>  2

Xaa Xaa Xaa Xaa Asp Gly Ser Asn Lys Xaa Xaa Ala Asp Ser Val Lys 
1               5                   10                  15      


Xaa 
    


<210>  3
<211>  17
<212>  PRT
<213>  Homo sapiens


<220>
<221>  MISC_FEATURE
<222>  (1)..(17)
<223>  Heavy Chain complementarity determining region 3 (CDR3).

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Xaa at position 4 is selected from Ile or Val.

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Xaa at position 5 is selected from Ser, Ala or Gly.

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  Xaa at position 9 is selected from Asn or Tyr.

<400>  3

Asp Arg Gly Xaa Xaa Ala Gly Gly Xaa Tyr Tyr Tyr Tyr Gly Met Asp 
1               5                   10                  15      


Val 
    


<210>  4
<211>  11
<212>  PRT
<213>  Homo sapiens


<220>
<221>  MISC_FEATURE
<222>  (1)..(11)
<223>  Light Chain complementarity determining region 1 (CDR1).

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Xaa at position 7 is selected from Ser or Tyr.

<400>  4

Arg Ala Ser Gln Ser Val Xaa Ser Tyr Leu Ala 
1               5                   10      


<210>  5
<211>  7
<212>  PRT
<213>  Homo sapiens


<220>
<221>  MISC_FEATURE
<222>  (1)..(7)
<223>  Light Chain complementarity determining region 2 (CDR2).

<400>  5

Asp Ala Ser Asn Arg Ala Thr 
1               5           


<210>  6
<211>  10
<212>  PRT
<213>  Homo sapiens


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)
<223>  Light Chain complementarity determining region 3 (CDR3).

<400>  6

Gln Gln Arg Ser Asn Trp Pro Pro Phe Thr 
1               5                   10  


<210>  7
<211>  126
<212>  PRT
<213>  Homo sapiens


<220>
<221>  MISC_FEATURE
<222>  (1)..(126)
<223>  heavy chain variable region sequences as presented in original 
       Figure 4

<220>
<221>  MISC_FEATURE
<222>  (1)..(30)
<223>  framework 1

<220>
<221>  MISC_FEATURE
<222>  (28)..(28)
<223>  Xaa at position 28 is selected from Ile or Thr.

<220>
<221>  MISC_FEATURE
<222>  (31)..(35)
<223>  complementarity determining region 1 (CDR1).

<220>
<221>  MISC_FEATURE
<222>  (36)..(49)
<223>  framework 2

<220>
<221>  MISC_FEATURE
<222>  (43)..(43)
<223>  Xaa at position 43 is selected from Lys or Asn.

<220>
<221>  MISC_FEATURE
<222>  (50)..(66)
<223>  complementarity determining region 2 (CDR2).

<220>
<221>  MISC_FEATURE
<222>  (50)..(50)
<223>  Xaa at position 50 is selected from Ile, Phe or Val.

<220>
<221>  MISC_FEATURE
<222>  (51)..(51)
<223>  Xaa at position 51 is selected from Ile or Met.

<220>
<221>  MISC_FEATURE
<222>  (52)..(52)
<223>  Xaa at position 52 is selected from Ser or Leu.

<220>
<221>  MISC_FEATURE
<222>  (53)..(53)
<223>  Xaa at position 53 is selected from Tyr or Phe.

<220>
<221>  MISC_FEATURE
<222>  (59)..(59)
<223>  Xaa at position 59 is selected from Lys or Tyr.

<220>
<221>  MISC_FEATURE
<222>  (60)..(60)
<223>  Xaa at position 60 is selected from Ser or Tyr.

<220>
<221>  MISC_FEATURE
<222>  (66)..(66)
<223>  Xaa at position 66 is selected from Asp or Gly.

<220>
<221>  MISC_FEATURE
<222>  (67)..(98)
<223>  framework 3

<220>
<221>  MISC_FEATURE
<222>  (70)..(70)
<223>  Xaa at position 70 is selected from Val or Ile.

<220>
<221>  MISC_FEATURE
<222>  (75)..(75)
<223>  Xaa at position 75 is selected from Ser or Pro.

<220>
<221>  MISC_FEATURE
<222>  (78)..(78)
<223>  Xaa at position 78 is selected from Thr or Ala.

<220>
<221>  MISC_FEATURE
<222>  (80)..(80)
<223>  Xaa at position 80 is selected from Tyr or Phe.

<220>
<221>  MISC_FEATURE
<222>  (94)..(94)
<223>  Xaa at position 94 is selected from Tyr or Phe.

<220>
<221>  MISC_FEATURE
<222>  (99)..(115)
<223>  complementarity determining region 3 (CDR3).

<220>
<221>  MISC_FEATURE
<222>  (102)..(102)
<223>  Xaa at position 102 is selected from Ile or Val.

<220>
<221>  MISC_FEATURE
<222>  (116)..(126)
<223>  J6 region

<400>  7

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Xaa Phe Ser Ser Tyr 
            20                  25                  30          


Ala Met His Trp Val Arg Gln Ala Pro Gly Xaa Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Xaa Xaa Xaa Xaa Asp Gly Ser Asn Lys Xaa Xaa Ala Asp Ser Val 
    50                  55                  60                  


Lys Xaa Arg Phe Thr Xaa Ser Arg Asp Asn Xaa Lys Asn Xaa Leu Xaa 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Xaa Tyr Cys 
                85                  90                  95      


Ala Arg Asp Arg Gly Xaa Ala Ala Gly Gly Asn Tyr Tyr Tyr Tyr Gly 
            100                 105                 110         


Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
        115                 120                 125     


<210>  8
<211>  108
<212>  PRT
<213>  Homo sapiens


<220>
<221>  MISC_FEATURE
<222>  (1)..(108)
<223>  light chain variable region sequences as presented in original 
       Figure 5

<220>
<221>  MISC_FEATURE
<222>  (1)..(23)
<223>  framework 1

<220>
<221>  MISC_FEATURE
<222>  (24)..(34)
<223>  complementarity determining region 1 (CDR1).

<220>
<221>  MISC_FEATURE
<222>  (35)..(49)
<223>  framework 2

<220>
<221>  MISC_FEATURE
<222>  (50)..(56)
<223>  complementarity determining region 2 (CDR2).

<220>
<221>  MISC_FEATURE
<222>  (57)..(88)
<223>  framework 3

<220>
<221>  MISC_FEATURE
<222>  (89)..(98)
<223>  complementarity determining region 3 (CDR3).

<220>
<221>  MISC_FEATURE
<222>  (99)..(108)
<223>  J3 region

<400>  8

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Tyr Ser Tyr 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro 
                85                  90                  95      


Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys 
            100                 105             


<210>  9
<211>  157
<212>  PRT
<213>  Homo sapiens


<220>
<221>  MISC_FEATURE
<222>  (1)..(157)
<223>  human TNF alpha monomer sequence

<400>  9

Val Arg Ser Ser Ser Arg Thr Pro Ser Asp Lys Pro Val Ala His Val 
1               5                   10                  15      


Val Ala Asn Pro Gln Ala Glu Gly Gln Leu Gln Trp Leu Asn Arg Arg 
            20                  25                  30          


Ala Asn Ala Leu Leu Ala Asn Gly Val Glu Leu Arg Asp Asn Gln Leu 
        35                  40                  45              


Val Val Pro Ser Glu Gly Leu Tyr Leu Ile Tyr Ser Gln Val Leu Phe 
    50                  55                  60                  


Lys Gly Gln Gly Cys Pro Ser Thr His Val Leu Leu Thr His Thr Ile 
65                  70                  75                  80  


Ser Arg Ile Ala Val Ser Tyr Gln Thr Lys Val Asn Leu Leu Ser Ala 
                85                  90                  95      


Ile Lys Ser Pro Cys Gln Arg Glu Thr Pro Glu Gly Ala Glu Ala Lys 
            100                 105                 110         


Pro Trp Tyr Glu Pro Ile Tyr Leu Gly Gly Val Phe Gln Leu Glu Lys 
        115                 120                 125             


Gly Asp Arg Leu Ser Ala Glu Ile Asn Arg Pro Asp Tyr Leu Asp Phe 
    130                 135                 140                 


Ala Glu Ser Gly Gln Val Tyr Phe Gly Ile Ile Ala Leu 
145                 150                 155         


<210>  10
<211>  18
<212>  DNA
<213>  Homo sapiens

<400>  10
ttggtccagt cggactgg                                                     18


<210>  11
<211>  18
<212>  DNA
<213>  Homo sapiens

<400>  11
cacctgcact cggtgctt                                                     18


<210>  12
<211>  30
<212>  DNA
<213>  Homo sapiens

<400>  12
cactgttttg agtgtgtacg ggcttaagtt                                        30


<210>  13
<211>  18
<212>  DNA
<213>  Homo sapiens

<400>  13
gccgcacgtg tggaaggg                                                     18


<210>  14
<211>  25
<212>  DNA
<213>  Homo sapiens

<400>  14
agtcaaggtc ggactggctt aagtt                                             25


<210>  15
<211>  28
<212>  DNA
<213>  Homo sapiens

<400>  15
gttgtcccct ctcacaatct tcgaattt                                          28


<210>  16
<211>  18
<212>  DNA
<213>  Homo sapiens

<400>  16
ggcggtagac tactcgtc                                                     18


<210>  17
<211>  7
<212>  PRT
<213>  Homo sapiens

<400>  17

Met Asp Trp Thr Trp Ser Ile 
1               5           


<210>  18
<211>  35
<212>  DNA
<213>  Homo sapiens

<400>  18
tttcgtacgc caccatggac tggacctgga gcatc                                  35


<210>  19
<211>  34
<212>  DNA
<213>  Homo sapiens

<400>  19
tttcgtacgc caccatgggg tttgggctga gctg                                   34


<210>  20
<211>  35
<212>  DNA
<213>  Homo sapiens

<400>  20
tttcgtacgc caccatggag tttgggctga gcatg                                  35


<210>  21
<211>  35
<212>  DNA
<213>  Homo sapiens

<400>  21
tttcgtacgc caccatgaaa cacctgtggt tcttc                                  35


<210>  22
<211>  35
<212>  DNA
<213>  Homo sapiens

<400>  22
tttcgtacgc caccatgggg tcaaccgcca tcctc                                  35


<210>  23
<211>  6
<212>  PRT
<213>  Homo sapiens

<400>  23

Thr Val Thr Val Ser Ser 
1               5       


<210>  24
<211>  36
<212>  DNA
<213>  Homo sapiens

<400>  24
gtgccagtgg cagaggagtc cattcaagct taagtt                                 36


<210>  25
<211>  5
<212>  PRT
<213>  Homo sapiens

<400>  25

Met Asp Met Arg Val 
1               5   


<210>  26
<211>  31
<212>  DNA
<213>  Homo sapiens

<400>  26
tttgtcgaca ccatggacat gagggtcctc c                                      31


<210>  27
<211>  28
<212>  DNA
<213>  Homo sapiens

<400>  27
tttgtcgaca ccatggaagc cccagctc                                          28


<210>  28
<211>  6
<212>  PRT
<213>  Homo sapiens

<400>  28

Thr Lys Val Asp Ile Lys 
1               5       


<210>  29
<211>  41
<212>  DNA
<213>  Homo sapiens

<400>  29
ctggtttcac ctatagtttg cattcagaat tcggcgcctt t                           41


<210>  30
<211>  35
<212>  DNA
<213>  Homo sapiens

<400>  30
catctccaga gacaattcca agaacacgct gtatc                                  35


<210>  31
<211>  35
<212>  DNA
<213>  Homo sapiens

<400>  31
gtagaggtct ctgttaaggt tcttgtgcga catag                                  35


<210>  32
<211>  19
<212>  PRT
<213>  Homo sapiens


<220>
<221>  MISC_FEATURE
<222>  (1)..(19)
<223>  Signal sequence for heavy chain variable region sequences as 
       presented in original Figure 4

<400>  32

Met Gly Phe Gly Leu Ser Trp Val Phe Leu Val Ala Leu Leu Arg Gly 
1               5                   10                  15      


Val Gln Cys 
            


<210>  33
<211>  20
<212>  PRT
<213>  Homo sapiens


<220>
<221>  MISC_FEATURE
<222>  (1)..(20)
<223>  Signal sequence for light chain variable region sequences as 
       presented in original Figure 5

<400>  33

Met Glu Ala Pro Ala Gln Leu Leu Phe Leu Leu Leu Leu Trp Leu Pro 
1               5                   10                  15      


Asp Thr Thr Gly 
            20  


<210>  34
<211>  428
<212>  DNA
<213>  Homo sapiens

<400>  34
atggggtttg ggctgagctg ggttttcctc gttgctcttt taagaggtgt ccagtgtcag       60

gtgcagctgg tggagtctgg gggaggcgtg gtccagcctg ggaggtccct gagactctcc      120

tgtgcagcct ctggttcacc ttcagtagct atgctatgca ctgggtccgc caggctccgg      180

caaggggctg gagtgggtgg cagttatatc atatgatgga aaataaatac tacgcagact      240

ccgtgaaggg ccgattcacc atctagagac aattccaaga acacgctgta tctgcaaatg      300

aacagccaga gctgaggaca cggctgtgta ttactgtgcg agagatcgag gtatatcagc      360

aggtggaata ctactactac tacggtatgg acgtctgggg gcaagggacc acggtcaccg      420

tctcctca                                                               428


<210>  35
<211>  387
<212>  DNA
<213>  Homo sapiens

<400>  35
atggaagccc cagctcagct tctcttcctc ctgctactct ggctcccaga taccaccgga       60

gaaattgtgt tgacacagtc tccagccacc ctgtctttgt ctccagggga aagagccacc      120

ctctcctgca gggccagtca gagtgttagc agctacttag cctggtacca acagaaacct      180

ggccaggctc ccaggctcct catctatgat gcatccaaca gggccactgg catcccagcc      240

aggttcagtg gcagtgggtc tgggacagac ttcactctca ccatcagcag cctagagcct      300

gaagattttg cagtttatta ctgtcagcag cgtagcaact ggcctccatt cactttcggc      360

cctgggacca aagtggatat caaacgt                                          387


<210>  36
<211>  456
<212>  PRT
<213>  Homo sapiens


<220>
<221>  MISC_FEATURE
<222>  (1)..(456)
<223>  Golimumab Heavy Chain (HC)

<400>  36

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Ser Ser Tyr 
            20                  25                  30          


Ala Met His Trp Val Arg Gln Ala Pro Gly Asn Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Phe Met Ser Tyr Asp Gly Ser Asn Lys Lys Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Asp Arg Gly Ile Ala Ala Gly Gly Asn Tyr Tyr Tyr Tyr Gly 
            100                 105                 110         


Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser 
        115                 120                 125             


Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr 
    130                 135                 140                 


Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro 
145                 150                 155                 160 


Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val 
                165                 170                 175     


His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser 
            180                 185                 190         


Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile 
        195                 200                 205             


Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val 
    210                 215                 220                 


Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 
225                 230                 235                 240 


Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 
                245                 250                 255     


Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 
            260                 265                 270         


Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val 
        275                 280                 285             


Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln 
    290                 295                 300                 


Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln 
305                 310                 315                 320 


Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala 
                325                 330                 335     


Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro 
            340                 345                 350         


Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr 
        355                 360                 365             


Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser 
    370                 375                 380                 


Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr 
385                 390                 395                 400 


Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 
                405                 410                 415     


Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe 
            420                 425                 430         


Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys 
        435                 440                 445             


Ser Leu Ser Leu Ser Pro Gly Lys 
    450                 455     


<210>  37
<211>  215
<212>  PRT
<213>  Homo sapiens


<220>
<221>  MISC_FEATURE
<222>  (1)..(215)
<223>  Golimumab Light Chain (LC)

<400>  37

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Tyr Ser Tyr 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro 
                85                  90                  95      


Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys Arg Thr Val Ala 
            100                 105                 110         


Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser 
        115                 120                 125             


Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu 
    130                 135                 140                 


Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser 
145                 150                 155                 160 


Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu 
                165                 170                 175     


Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val 
            180                 185                 190         


Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys 
        195                 200                 205             


Ser Phe Asn Arg Gly Glu Cys 
    210                 215 


<210>  38
<211>  456
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HC N43D

<400>  38

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Ser Ser Tyr 
            20                  25                  30          


Ala Met His Trp Val Arg Gln Ala Pro Gly Asp Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Phe Met Ser Tyr Asp Gly Ser Asn Lys Lys Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Asp Arg Gly Ile Ala Ala Gly Gly Asn Tyr Tyr Tyr Tyr Gly 
            100                 105                 110         


Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser 
        115                 120                 125             


Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr 
    130                 135                 140                 


Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro 
145                 150                 155                 160 


Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val 
                165                 170                 175     


His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser 
            180                 185                 190         


Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile 
        195                 200                 205             


Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val 
    210                 215                 220                 


Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 
225                 230                 235                 240 


Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 
                245                 250                 255     


Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 
            260                 265                 270         


Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val 
        275                 280                 285             


Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln 
    290                 295                 300                 


Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln 
305                 310                 315                 320 


Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala 
                325                 330                 335     


Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro 
            340                 345                 350         


Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr 
        355                 360                 365             


Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser 
    370                 375                 380                 


Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr 
385                 390                 395                 400 


Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 
                405                 410                 415     


Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe 
            420                 425                 430         


Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys 
        435                 440                 445             


Ser Leu Ser Leu Ser Pro Gly Lys 
    450                 455     


